English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/82528
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy

AuthorsLiekens, S.; Bronckaers, A.; Peréz-Pérez, María-Jesús ; Balzarini, Jan
Issue Date2007
CitationBiochemical Pharmacology 74: 1555- 1567 (2007)
AbstractThymidine phosphorylase (TP) is a key enzyme in the pyrimidine nucleoside salvage pathway, but it also recognizes and inactivates various anti-cancer chemotherapeutic agents. Moreover, TP is identical to platelet-derived endothelial cell growth factor (PD-ECGF), an angiogenic factor with anti-apoptotic properties. Increased expression of PD-ECGF/TP is found in many tumor and stromal cells, and elevated TP levels are associated with aggressive disease and/or poor prognosis. Thus, progression and metastasis of TP-expressing tumors might be abrogated by TP inhibitors that are used as single agents or in combination with (TP-sensitive) nucleoside analogues. On the other hand, increased TP activity in tumors may be exploited for the tumor-specific activation of fluoropyrimidine prodrugs, such as capecitabine. This review will focus on the different biological activities of PD-ECGF/TP and their implications for cancer progression and treatment. © 2007 Elsevier Inc. All rights reserved.
Identifiersdoi: 10.1016/j.bcp.2007.05.008
issn: 0006-2952
e-issn: 1873-2968
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.